within Pharmacolibrary.Drugs.ATC.C;

model C04AX32
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 25 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 30 / 1000000,
    adminCount     = 1,
    Vd             = 0.03,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Fasudil is a selective Rho-kinase inhibitor primarily used in the treatment of cerebral vasospasm following subarachnoid hemorrhage and has been investigated for use in pulmonary hypertension and other vascular conditions. It is approved in Japan but not widely approved elsewhere.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters for adult healthy male volunteers after intravenous administration.</p><h4>References</h4><ol><li><p>Wolff, AW, et al., &amp; Lingor, P (2024). SAFE-ROCK: A Phase I Trial of an Oral Application of the ROCK Inhibitor Fasudil to Assess Bioavailability, Safety, and Tolerability in Healthy Participants. <i>CNS drugs</i> 38(4) 291–302. DOI:<a href=&quot;https://doi.org/10.1007/s40263-024-01070-7&quot;>10.1007/s40263-024-01070-7</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38416402/&quot;>https://pubmed.ncbi.nlm.nih.gov/38416402</a></p></li><li><p>Nahar, K, et al., &amp; Ahsan, F (2014). Peptide-coated liposomal fasudil enhances site specific vasodilation in pulmonary arterial hypertension. <i>Molecular pharmaceutics</i> 11(12) 4374–4384. DOI:<a href=&quot;https://doi.org/10.1021/mp500456k&quot;>10.1021/mp500456k</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25333706/&quot;>https://pubmed.ncbi.nlm.nih.gov/25333706</a></p></li><li><p>Gupta, V, et al., &amp; Ahsan, F (2013). Liposomal fasudil, a rho-kinase inhibitor, for prolonged pulmonary preferential vasodilation in pulmonary arterial hypertension. <i>Journal of controlled release : official journal of the Controlled Release Society</i> 167(2) 189–199. DOI:<a href=&quot;https://doi.org/10.1016/j.jconrel.2013.01.011&quot;>10.1016/j.jconrel.2013.01.011</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/23353807/&quot;>https://pubmed.ncbi.nlm.nih.gov/23353807</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end C04AX32;
